13 results about "Hypericin" patented technology

The present application relates to a kind of preparation method of Fugunkang composition and its detection method, the preparation method is cut into section, first using red koji and saccharomyces cerevisiae combined fermentation extraction, dregs is extracted with water before boiling, concentrate and extract the fermentation liquor and water, it is obtained.The metabolic function of microorganism is fully utilized, promote the release and absorption of effective components of traditional Chinese medicine in vivo, so as to improve the curative effect of traditional Chinese medicine, reduce the side effect of traditional Chinese medicine.The detection method includes spray agent in just bed, parsnip medicine thin layer identification and the content detection of rutin, hypericin;The thin layer identification can identify just bed and parsnip medicine under the same chromatographic condition, the content detection increases the content detection of hypericin on the basis of original, and the content of rutin and hypericin can be determined simultaneously, save the detection cost, ensure the quality of raw material and finished product.

The invention discloses a cathepsin B activated chemiluminescent nanoparticle. The cathepsin B activated chemiluminescent nanoparticle is prepared from cat B-C-550, hypericin and DSPE-mPEG2000 (Distearoyl Phosphate Polyethylene-mPEG (Polyethylene Glycol) 2000 in a self-assembly manner; the structure of the cat B-C-550 is as shown in a formula I in the specification. The invention discloses an application of cat B enzyme activated chemiluminescent nanoparticles in preparation of reagents or drugs for screening or diagnosing tumors. The invention discloses an application of cat B enzyme activated chemiluminescent nanoparticles in preparation of a cancer imaging reagent and / or a medicine for treating tumors. According to the invention, chemiluminescence imaging and in-situ cancer PDT treatment without external exciting light are realized. The cat B enzyme response type chemiluminescent nanoparticles are high in stability and can be effectively targeted and enriched at tumor focus parts.

The present invention relates to a kit of parts for an oral care device, comprising a light-emitting element and an oral composition comprising curcumin, curcuminoids, curcumin derivatives, or hypericin.

The present invention discloses a SAMe, 5-HTP, and St. John's wort compound nutritional supplement for emotional support and joint care, comprising 15-25 parts of S-adenosylmethionine, 5-10 parts of 5-hydroxytryptophan, 3-8 parts of St. John's wort extract, 8-15 parts of sodium chondroitin sulfate, 2-5 parts of sodium hyaluronate, 0.5-1.2 parts of vitamin B6, 1-3 parts of vitamin E, 4-9 parts of phosphatidylserine, and pharmaceutical excipients. The weight ratio of S-adenosylmethionine to 5-hydroxytryptophan is 3:1-5:2, the weight ratio of St. John's wort extract to 5-hydroxytryptophan is 0.6:1-0.8:1, and the weight ratio of the joint-care agents to the total core active ingredients is 10:3-20:3. The hypericin content in the St. John's wort extract is not less than 3%. By optimizing the component ratios and utilizing synergistic functional excipients, the present invention achieves dual synergy in emotional support and joint care, with high product stability and excellent bioavailability.

The invention relates to a composite hydrogel dressing as well as a preparation method and application thereof, and relates to the technical field of medical wound dressings. The SF / SA-H hydrogel dressing is obtained by taking silk fibroin (SF) and sodium alginate (SA) as a mixed solvent, adding hyperoside, mixing, pouring at a constant temperature, curing and demolding, the dressing realizes dual synergistic effects of antibiosis and anti-inflammation, has the characteristics of easily available raw materials, convenience in production and high safety while meeting the curative effect of DFU wound treatment, and has a wide application prospect. Large-scale production and clinical transformation are easy to realize, and the method has a wide medical application prospect.

The application belongs to the field of new adjuvants and new dosage forms of pharmaceutical preparations, and particularly relates to a type I and type II immunogenic cell death inducer ion pairing engineered nanoassemblies as well as construction and application thereof. The nanoassemblies are composed of type I ICD inducers, type II ICD inducers, hydrophobic auxiliary counterions and amphiphilic lipid ion pairing. The type I ICD inducer is selected from mitoxantrone, doxorubicin, oxaliplatin or cyclophosphamide; the type II ICD inducer is selected from hypericin; and the hydrophobic auxiliary counterion is selected from cholesteryl sodium sulfate, cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, glycolcholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid lysine derivative, oleanolic acid and ursolic acid. The type I and type II ICD inducers are combined in the application, and have a synergistic tumor treatment effect.

There are described compositions comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACTI peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof).

The present invention relates to a composition comprising a mixture of molecules, said mixture comprising at least chrysin, pinocembrin and CAPE, for its use in the prevention or treatment of neuroinflammation and / or diseases or disorders associated with neuroinflammation.

This invention belongs to the field of preservation technology, and specifically relates to a method for preparing an emulsion co-encapsulating hypericin and Sichuan pepper oil, and its application in chili pepper preservation. This invention solves the technical problems of low water solubility and poor bioavailability of hypericin alone, and high volatility and poor stability of Sichuan pepper oil alone, making it difficult to achieve long-lasting antibacterial effects, and the fact that the two have never been used in synergistic antibacterial applications. This invention uses Tween 80 as an emulsifier, dissolving it in deionized water to obtain an aqueous phase containing Tween 80; Sichuan pepper oil and Tween 80 are ultrasonically mixed, and hypericin is added and ultrasonically mixed to obtain an oil phase; the oil phase is then added dropwise to the aqueous phase and stirred, and homogenized using a high-speed homogenizer to obtain a crude emulsion; the crude emulsion is then treated in an ultrasonic cell disruptor to obtain a hypericin-Sichuan pepper oil nanoemulsion containing 5%~7% of both Tween 80 and Sichuan pepper oil by volume. The emulsion exhibits excellent stability, effectively inhibiting pathogens, delaying fruit and vegetable spoilage, and improving preservation effects.

The invention relates to the technical field of treatment of neurodegenerative diseases, in particular to application of a Gpnmb gene in related tau protein diseases. The invention relates to a pharmaceutical composition, which comprises a small molecule compound capable of activating a v-ATP enzyme subunit ATP6V0D1 and / or ATP6V0D2, and is used for recovering lysosomal acidification and tau protein degradation capability of Gpnmb-deficient microglial cells, the small molecule compound is hypericin, and the pharmaceutical composition is used for treating neurodegenerative diseases related to tau protein accumulation. The application of the Gpnmb gene in related tau protein lesions reveals that deletion of the Gpnmb gene can aggravate pathological changes, neurodegenerative lesions and cognitive impairment of tau protein, clarifies the key effect of the Gpnmb gene in neuroprotection, and explains that Gpnmb regulates assembling of a v-ATP enzyme subunit ATP6V0D1 / D2 and maintains lysosomal acidification so as to promote degradation of the tau protein from the molecular level, so that the application of the Gpnmb gene in the related tau protein lesions is realized, and the application of the Gpnmb gene in the related tau protein lesions is realized. And a new target spot is provided for treatment.

The application belongs to the technical field of medicines, and particularly relates to application of hyperforin in preparation of medicines for treating inflammatory bowel disease, and proves that hyperforin treatment can increase the colon length of a DSS-induced mouse colitis model, improve the pathological structure and clinical symptoms of the colon tissue of the model mouse, and significantly up-regulate ZO-1 protein and improve the levels of related inflammatory factors such as TNF-alpha, IL-6 and IL-1beta, and has significant anti-ulcerative colitis activity, and the hyperforin can provide a new approach for preparing medicines for treating ulcerative colitis in the future.

The application provides application of hypericin in preparation of a medicine for resisting St. Louis encephalitis virus infection. The application has the beneficial effect that the hypericin has a significant inhibitory effect on NS2B-NS3 protease activity in the St. Louis encephalitis virus, can be used as an inhibitor of the NS2B-NS3 protease in the St. Louis encephalitis virus, and is expected to become a potential medicine for resisting St. Louis encephalitis virus infection.

Provided are a product for treating Helicobacter pylori-negative chronic atrophic gastritis with intestinal metaplasia and / or with dysplasia, for reversing the pathology of gastric precancerous lesions, and for preventing the occurrence of gastric cancer, and a treatment method therefor. The product is a lotus leaf extract, and representative active ingredients thereof include, but are not limited to, isoquercetin, quercetin-3-O-glucuronide, hypericin, and nuciferine. The use comprises at least one of treating Helicobacter pylori-negative chronic atrophic gastritis with intestinal metaplasia and / or with dysplasia, reversing gastric precancerous lesions, and preventing the occurrence of gastric cancer. In vitro experiments show that the lotus leaf extract can inhibit malignant proliferation of gastric precancerous lesion epithelial cells and reduce the active oxygen level thereof. In vivo experiments show that the lotus leaf extract can effectively improve the pathology of the Helicobacter pylori-negative gastric precancerous lesions and prevent the occurrence of gastric cancer in animal models. Clinical trials have shown that the lotus leaf extract can effectively treat the pathological conditions and clinical symptoms in patients with the Helicobacter pylori-negative chronic atrophic gastritis with intestinal metaplasia and / or with dysplasia.